TRCT
SGMT icon

Tower Research Capital (TRC)’s Sagimet Biosciences SGMT Stock Holding History

Tower Research Capital (TRC)’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8K Buy
2,043
+402
+24% +$2.73K ﹤0.01% 3749
2026
Q1 		$8.57K Buy
+1,641
New +$9.15K ﹤0.01% 3963
2025
Q4 		– Sell
-541
Closed -$3.71K – 5538
2025
Q3 		$3.71K Sell
541
-4,066
-88% -$33K ﹤0.01% 4462
2025
Q2 		$35.1K Buy
+4,607
New +$19.4K ﹤0.01% 3274
2024
Q4 		– Sell
-5,432
Closed -$15K – 5966
2024
Q3 		$15K Sell
5,432
-16,412
-75% -$50.6K ﹤0.01% 3425
2024
Q2 		$74.7K Buy
21,844
+19,111
+699% +$87.7K ﹤0.01% 2795
2024
Q1 		$14.8K Buy
2,733
+729
+36% +$5.24K ﹤0.01% 3283
2023
Q4 		$10.9K Sell
2,004
-522
-21% -$2.46K ﹤0.01% 4193
2023
Q3 		$22.2K Buy
+2,526
New +$33.6K ﹤0.01% 3278

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Tower Research Capital (TRC)'s SGMT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Sagimet Biosciences (SGMT) stake by 24% in Q2 2026, buying an estimated $2.73K and bringing the position to 2,043 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

Tower Research Capital (TRC) first reported a position in SGMT in Q3 2023 and has held it in 9 quarters since. The position peaked at $74.7K in Q2 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Tower Research Capital (TRC) held 2,043 shares of Sagimet Biosciences worth $15.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 402 Sagimet Biosciences shares in Q2 2026, an estimated $2.73K.
  • Sagimet Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3749 holding.
  • Tower Research Capital (TRC) first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Sagimet Biosciences position peaked at $74.7K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.